Identification and Characterization of NDT 9513727 [N,N-bis(1,3-Benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a Novel, Orally Bioavailable C5a Receptor Inverse Agonist
Open Access
- 27 August 2008
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 327 (3), 898-909
- https://doi.org/10.1124/jpet.108.141572
Abstract
The complement system represents an innate immune mechanism of host defense that has three effector arms, the C3a receptor, the C5a receptor (C5aR), and the membrane attack complex. Because of its inflammatory and immune-enhancing properties, the biological activity of C5a and its classical receptor have been widely studied. Because specific antagonism of the C5aR could have therapeutic benefit without affecting the protective immune response, the C5aR continues to be a promising target for pharmaceutical research. The lack of specific, potent and orally bioavailable small-molecule antagonists has limited the clinical investigation of the C5aR. We report the discovery of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a small-molecule, orally bioavailable, selective, and potent inverse agonist of the human C5aR. NDT 9513727 was discovered based on the integrated use of in vitro affinity and functional assays in conjunction with medicinal chemistry. NDT 9513727 inhibited C5a-stimulated responses, including guanosine 5′-3-O-(thio)triphosphate binding, Ca2+ mobilization, oxidative burst, degranulation, cell surface CD11b expression and chemotaxis in various cell types with IC50s from 1.1 to 9.2 nM, respectively. In C5a competition radioligand binding experiments, NDT 9513727 exhibited an IC50 of 11.6 nM. NDT 9513727 effectively inhibited C5a-induced neutropenia in gerbil and cynomolgus macaque in vivo. The findings suggest that NDT 9513727 may be a promising new entity for the treatment of human inflammatory diseases.Keywords
This publication has 30 references indexed in Scilit:
- Extended haplotypes in the complement factor H (CFH) and CFH‐related (CFHR) family of genes protect against age‐related macular degeneration: Characterization, ethnic distribution and evolutionary implicationsAnnals of Medicine, 2006
- ROLE OF C5A IN INFLAMMATORY RESPONSESAnnual Review of Immunology, 2005
- Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse AgonismMolecular Pharmacology, 2004
- Identification of a Potent and Orally Active Non-peptide C5a Receptor AntagonistPublished by Elsevier ,2002
- Arthritis Critically Dependent on Innate Immune System PlayersImmunity, 2002
- An Activation Switch in the Ligand Binding Pocket of the C5a ReceptorPublished by Elsevier ,2001
- Inverse agonism at G protein‐coupled receptors: (patho)physiological relevance and implications for drug discoveryBritish Journal of Pharmacology, 2000
- Pharmacological characterization of antagonists of the C5a receptorBritish Journal of Pharmacology, 1999
- Purification and Reconstitution of the Ca2+-Pumping ATPase of Red Blood CellsMethods, 1994
- Human C5a and C5a analogs as probes of the neutrophil C5a receptorMolecular Immunology, 1980